BioAtla Investor Presentation Deck

Phase 2 CAB-AXL (BA3011) NSCLC Dose Optimization In-line with FDA Project Optimus 2Q3W dosing regimen 11 patients treated ● 4 patients have been evaluable (3 SD and 1 PD) as of 12/4; target agnostic data expected in 1H 2024 ● 3Q4W dosing regimen Suboptimal compliance observed and enrollment has been discontinued ● bicatla Benefit-Risk profile observed to date with 1.8 mg/kg Q2W supports advancing this dose in registrational studies Rotow J, Dy GK, Camidge DR. Poster presented at: International Association for the Study of Lung Cancer 2023 North America Conference on Lung Cancer; December 1-3, 2023; Chicago, IL. BioAtla| Overview 39

View entire presentation